Yesterday, the largest U.S. retailer$Walmart (WMT) $The gap opened more than 2% higher to a record high of $117.6. According to the news, Walmart will replace AstraZeneca as a constituent stock of the Nasdaq 100 Index, replacing AstraZeneca's position in the Nasdaq 100 Index. The adjustment will take effect on January 20, 2026.Strategic trends: Cooperate with Google to launch AI shopping assistant Sparky to promote the transformation of "conversational e-commerce"; Expand cooperation with Google subsidiary Wing to cover emergency merchandise delivery across the United States.Market sentiment and institutional views: Among the 43 institutions, 14 "strongly recommend" and 29 "buy", with an average target price of $121.71 (a 3.2% premium to the current p
Walmart Guidance Misses, $30B Buyback: Stock Peaks?
Walmart posted $190.66B Q4 revenue (vs $190.58B est.) and $0.74 EPS (vs $0.73 est.), while announcing a fresh $30B buyback. Yet guidance disappointed: FY2027 EPS is projected at $2.75–$2.85, below the $2.97 consensus. Shares fell over 2% premarket. With a $1T market cap and strong defensive flows, Walmart has been a clear winner in the AI-driven rotation toward supply chain efficiency and essentials. But slowing earnings momentum and macro uncertainty raise questions. Is this consolidation after a massive run? Or an early signal that defensive leadership is peaking?
+ Follow
+0